Profile for European Patent Office Patent: 1856135
✉ Email this page to a colleague
| Country | SPC | SPC Expiration |
|---|---|---|
| Netherlands | 301039 | ⤷ Start Trial |
| Denmark | CA 2020 00018 | ⤷ Start Trial |
| Luxembourg | LUC00153 | ⤷ Start Trial |
| Germany | 122020000021 | ⤷ Start Trial |
US Patent Family Members and Approved Drugs for European Patent Office Patent: 1856135
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| ⤷ Start Trial | Sep 4, 2031 | Rigel Pharms | TAVALISSE | fostamatinib disodium |
| ⤷ Start Trial | Mar 28, 2026 | Rigel Pharms | TAVALISSE | fostamatinib disodium |
| ⤷ Start Trial | Jun 12, 2026 | Rigel Pharms | TAVALISSE | fostamatinib disodium |
| ⤷ Start Trial | Jan 19, 2026 | Rigel Pharms | TAVALISSE | fostamatinib disodium |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
